Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng JiangDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USAShengqing GuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USADeng PanDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USAJingxin FuSchool of Life Science and Technology, Tongji University, Shanghai, ChinaAvinash SahuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USAXihao HuDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USAZiyi LiSchool of Life Science and Technology, Tongji University, Shanghai, ChinaNicole TraughDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAXia BuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USABo LiThe University of Texas Southwestern Medical CenterJun LiuDepartment of Statistics, Harvard University, Cambridge, MA, USAGordon J. FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAMyles BrownCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USAKai W. WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USAX. Shirley LiuCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected]
2018en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
3 ta iqtibos0 ta foydalanilgan manba